ArticleFrontiers in neuroscience2025
The
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reelin, a glycoprotein, plays an essential role in the development and maturation of neural circuits in the cerebral cortex during embryonic and postnatal stages. Animal and human studies suggest that insufficient reelin signaling due to RELN mutations may alter the functional properties of the prefrontal cortex and contribute to cortical dysplasia in the frontal and temporal lobes. A heterozygous missense mutation in RELN, rs362691 (p. Leu997Val), has been proposed to increase susceptibility to autism spectrum disorder (ASD). Based on the empathizing-systemizing theory, this study examined whether the rs362691 variant affects cortical thickness and modulates autism-related cognitive traits in typically developing children and adolescents. We hypothesized that individuals carrying the heterozygous Val/Leu genotype would exhibit greater prefrontal cortical thickness than those with the Val/Val genotype, and that this morphological difference would correlate with autistic cognitive traits. We also explored potential thickness differences in the frontal and temporal cortices. Our results showed that the heterozygous Val/Leu group did not differ from the Val/Val group in empathizing or systemizing trait scores. However, individuals with the Val/Leu genotype exhibited increased cortical thickness in the medial prefrontal sulci, which correlated with individual differences in systemizing traits. No significant association was observed between cortical thickness and empathizing traits across the whole brain. Additionally, greater cortical thickness was observed in the right superior temporal sulcus (STS), although this morphological difference was not associated with empathizing or systemizing traits. These findings suggest that while the rs362691 variant does not significantly influence autism-related cognitive styles per se, it may alter cortical morphology in prefrontal regions functionally linked to systemizing traits in typically developing individuals. Several methodological limitations in the employed data should be considered. Future studies with larger, age-appropriate cohorts and standardized personality measures will be necessary to validate and extend these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.